ArticleNature communications2022
Invariant surface glycoprotein 65 of Trypanosoma brucei is a complement C3 receptor.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Thermo-related degeneration of stumpy forms of Trypanosoma brucei, the pathogen of African sleeping sickness.Advanced biotechnology · 2025Article
- From fat storage to immune hubs: the emerging role of adipocytes in coordinating the immune response to infection.The FEBS journal · 2025Review
- Roles of cytokines in modulatingFrontiers in parasitology · 2025Article
- Article
- Beyond the VSG layer: Exploring the role of intrinsic disorder in the invariant surface glycoproteins of African trypanosomes.PLoS pathogens · 2024Article
- A conserved trypanosomatid differentiation regulator controls substrate attachment and morphological development in Trypanosoma congolense.PLoS pathogens · 2024Article
- Recent Progress in the Detection of Surra, a Neglected Disease Caused byMicroorganisms · 2023Review
- Trypanosomes and complement: more than one way to die?Trends in parasitology · 2023Review
- Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis.Nature communications · 2023Article
- Chemical Inhibition of Bromodomain Proteins in Insect-Stage African Trypanosomes Perturbs Silencing of the Variant Surface Glycoprotein Repertoire and Results in Widespread Changes in the Transcriptome.Microbiology spectrum · 2023Article
- Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction.Nature communications · 2023Article
- The ElusivePathogens (Basel, Switzerland) · 2023Review
- The role of invariant surface glycoprotein 75 in xenobiotic acquisition by African trypanosomes.Microbial cell (Graz, Austria) · 2023Article
- TUSK: a ubiquitin hydrolase complex modulating surface protein abundance in trypanosomes.Frontiers in parasitology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
Abstract
African trypanosomes are extracellular pathogens of mammals and are exposed to the adaptive and innate immune systems. Trypanosomes evade the adaptive immune response through antigenic variation, but little is known about how they interact with components of the innate immune response, including complement. Here we demonstrate that an invariant surface glycoprotein, ISG65, is a receptor for complement component 3 (C3). We show how ISG65 binds to the thioester domain of C3b. We also show that C3 contributes to control of trypanosomes during early infection in a mouse model and provide evidence that ISG65 is involved in reducing trypanosome susceptibility to C3-mediated clearance. Deposition of C3b on pathogen surfaces, such as trypanosomes, is a central point in activation of the complement system. In ISG65, trypanosomes have evolved a C3 receptor which diminishes the downstream effects of C3 deposition on the control of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.